<DOC>
	<DOCNO>NCT01825551</DOCNO>
	<brief_summary>The aim study evaluate effect Granulocyte Colony Stimulating Factor ( GCSF ) treatment Amyotrophic Lateral Sclerosis ( ALS ) patient .</brief_summary>
	<brief_title>The Effect GCSF Treatment ALS Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>age 18 85 definite probable ALS accord revise El Escorial criterion maximum 2 year initiation symptom study entry mild moderate disability accord revise ALS functional rating scale ( ALSFRSr ) familial ALS pregnancy lactation myeloproliferative hematologic disorder active immunological disease liver renal heart disease HIV positive significant cognitive disorder hypersensitivity GCSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Granulocyte Colony Stimulating Factor</keyword>
</DOC>